Research Grade Revdofilimab (DHE43205)

Research Grade Revdofilimab (DHE43205) Suppliers list
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Guangzhou Hongyuan Chemical Co.,Ltd  
Tel: 15817493340
Email: 981810490@qq.com
Company Name: Biolab Reagents  
Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Company Name: Shanghai Yifei Biotechnology Co. , Ltd.  
Tel: 021-65675885 18964387627
Email: customer_service@efebio.com
Company Name: Wuhan Acumen Bio-Technology Co.,ltd  
Tel: 027-027-16602739303 16602739303
Email: 673003916@qq.com

Research Grade Revdofilimab (DHE43205) manufacturers

  • Revdofilimab
  • Revdofilimab pictures
  • $263.00
  • 2026-07-13
  • CAS:2230138-89-1
  • Purity: 98.80%
  • Supply Ability: 10g
Research Grade Revdofilimab (DHE43205) Basic information
Product Name:Research Grade Revdofilimab (DHE43205)
Synonyms:Research Grade Revdofilimab (DHE43205);Research Grade Revdofilimab;Revdofilimab (anti-CD134)
CAS:2230138-89-1
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Research Grade Revdofilimab  (DHE43205) Structure
Research Grade Revdofilimab (DHE43205) Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Research Grade Revdofilimab (DHE43205) Usage And Synthesis
UsesRevdofilimab (ABBV-368) is a human IgG1 agonist monoclonal antibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory T cell subsets and T regulatory cells[1].
References[1] A. Spira, et al. Safety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors. ABSTRACTS IMMUNOTHERAPY OF CANCER|VOLUME 29, SUPPLEMENT 8,VIII409,OCTOBER 2018
Research Grade Revdofilimab (DHE43205) Preparation Products And Raw materials
Tag:Research Grade Revdofilimab (DHE43205)(2230138-89-1) Related Product Information
Rocatinlimab N-(2-Methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea Orexin A (17-33) MK 6096 EMPA Vonlerolizumab